PLUS1
1.32
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aclaris Therapeutics Inc | ACRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 1.32 | 0.00 | 0.00 | 0.00 | 1.32 | 07:12:20 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.31 | 1.38 | 0.07 | 5.07% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.32 | USD |
Aclaris Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 55.26M | 41.87M | 39.89M | $ 12.98M | $ - | -3.90 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 21.00 | 4.70% |
Aclaris Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/27/2020 | 07:04 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/26/2020 | 16:01 | GlobeNewswire Inc. | Aclaris Therapeutics to Present at the Jefferies Virtual.. |
| 5/15/2020 | 07:14 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/07/2020 | 17:04 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) |
| 5/07/2020 | 16:41 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 5/07/2020 | 16:20 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/07/2020 | 16:01 | GlobeNewswire Inc. | Aclaris Therapeutics Reports First Quarter 2020 Financial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.27 | 1.41 | 1.26 | 1.34 | 187,727 | 0.05 | 3.94% |
| 1 Month | 1.27 | 1.50 | 1.16 | 1.32 | 196,062 | 0.05 | 3.94% |
| 3 Months | 1.00 | 1.50 | 0.70 | 1.13 | 257,917 | 0.32 | 32.0% |
| 6 Months | 1.64 | 2.65 | 0.70 | 1.54 | 459,239 | -0.32 | -19.51% |
| 1 Year | 4.67 | 5.50 | 0.70 | 1.62 | 903,300 | -3.35 | -71.73% |
| 3 Years | 23.59 | 30.08 | 0.70 | 7.63 | 548,773 | -22.27 | -94.4% |
| 5 Years | 11.94 | 33.88 | 0.70 | 9.72 | 401,825 | -10.62 | -88.94% |
Aclaris Therapeutics Description
| Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively. |
